TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Stress Reduction and Cardiovascular Disease Morbidity and Mortality
Brief Summary: This randomized controlled clinical trial tests the hypothesis that a selected stress reduction approach, the Transcendental Meditation program will reduce all-cause mortality, myocardial infarction and stroke in African American patients with coronary heart disease. Secondary hypotheses include effects on other cardiovascular clinical events, blood pressure and psychosocial stress.


Options:
A: Inclusion Criteria:

* Patients diagnosed with atrial fibrillation.
* Relative to patient with atrial fibrillation.
* To be over 18 years old .

Exclusion Criteria:

* Unwillingness to participate in the study.
* Other complicating illness'.
* Language difficulties that prevent answering surveys.
* Participation in another study.
* Accommodation outside the hospital's catchment area.
B: Inclusion Criteria:

* Adult aged between 18 and 65 years
* Obese (BMI \>= 30)
* Recruited from the nutrition pole of Ambroise Paré Hospital
* Diagnosed with Binge-Eating Disorder (BED) according to DSM5 criteria
* Informed consent provided during inclusion interview

Exclusion Criteria:

* Already participating in a clinical trial
* Bariatric surgery patients (except for gastric band removed at least 3 years before)
* Planned bariatric surgery
* Central obese (genetic)
* Pregnant women
* No internet access at home
* Difficulties to understand French language
* Patients under social protection
* Cognitive dysfunctions in understanding simple guidelines provided by the paramedical staff (e.g., diet or exercise guidelines)
* Auditory disorders not allowing to hear audio files
* Blurred vision not allowing to use Internet
C: Inclusion Criteria:

* age 18-65 years
* current smoker with history of \>5 cigarettes/day for past year (and expired carbon monoxide \>6 parts per million \[ppm\])
* motivated to quit within next 30 days
* valid home address in the greater Atlanta, Georgia area
* functioning telephone number
* own a mobile phone with text messaging capacity
* can speak, read, and write in English
* at least a sixth-grade level of health literacy

Exclusion Criteria:

* contraindication for nicotine patch
* active substance abuse/dependence
* regular use of tobacco products other than cigarettes
* current use of tobacco cessation medications
* pregnancy or lactation
* household member enrolled in the study
* current diagnosis of schizophrenia or bipolar disorder, or use of antipsychotic medications
* clinically significant depressive symptoms
D: Inclusion Criteria:

African American men and women with documented coronary heart disease defined a coronary angiogram demonstrating the presence of one more coronary arteries with \> or = 50% stenosis.

Exclusion Criteria:

acute MI, stroke or coronary revascularization within the previous three months; symptomatic heart failure with EF \< 20%; dementia or other cognitive impairment determined clinically; and non-cardiac life threatening illness.

-

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Early Nutrient Intake on Growth and Body Composition
Brief Summary: The primary objective of the study is to compare the growth of infants fed standard infant formula with infants fed a reduced calorie and protein formula.


Options:
A: Inclusion Criteria:

* Previous participation in infant formula controlled protein study
* Body composition data from 6 month of age available
* Consent obtained from legal representative
* Within age parameters specified in protocol around the 3 and 5 year age points

Exclusion Criteria:

* Unable to endure testing procedures upon evaluation of the Investigator
* Outside the age range of the study
B: Inclusion Criteria:

* good health
* singleton birth with gestational age 37-42 weeks
* infant's birth weight \>or = to 2500 grams
* exclusive breastfeeding or exclusively formula feeding
* within a defined geographical boundary
* mother has no problems communicating in English

Exclusion Criteria:

* adverse maternal, fetal or infant medical history
* congenital disease or malformation affecting growth or development
* illness or social problems in mother or infant
* temporary residents
C: Inclusion Criteria:

* Singleton, 10-14 days of age at randomization
* Term infant with birth weight of a minimum of 2500 grams
* Solely formula fed
* Signed Informed Consent and Protected Health Information

Exclusion Criteria:

* Anemia at time of birth
* Current use of iron or iron-containing supplements
* History of underlying metabolic or chronic disease or immunocompromised
* Feeding difficulties or formula intolerance
D: Inclusion Criteria:

* Full-term newborn (≥37 weeks of gestation)
* Birth weight ≥2500 g and ≤4000 g
* Apgar score \> 8
* Infants from birth to 40 days of age at the time of enrollment
* Mothers voluntarily elected to exclusively breast-feed or formula-feed her newborn.

Exclusion Criteria:

* Infants with congenital heart defect, congenital illness or malformations, severe gastrointestinal disease, kidney, liver, central nervous system, or metabolic disease, or born from mothers with gestational diabetes.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Investigations on Improving Docosahexaenoic and Arachidonic Acid Content in Preterm Infant Formula
Brief Summary: The investigators examined the effect of different levels of docosahexaenoic aicd (a long chain polyunsaturated fatty acid) intake on the fatty acid composition of plasma and erythrocyte phospholipids and on the maturity of visually evoked potentials in preterm infants. As a secondary outcome the conversion of linoleic acid and alpha linolenic acid into their corresponding long chain polyunsaturated fatty acids was studied.

Preterm infants were randomized in a double-blind fashion to one of three formulas containing different amounts of docosahexaenoic acid during the first two weeks of postnatal life. A control group received human milk. Blood samples were collected at study entry and 14 and 28 days thereafter. Uniformly 13C-labeled linoleic acid and alpha linolenic acid were applied orally before blood sampling at day 28. At postconceptional ages 48 weeks and 56 weeks visually evoked potentials were recorded.


Options:
A: Inclusion Criteria:

* preterm birth
* birth weight between 1000 and 2200 g
* more than 80 % of energy intake from infant formula or human milk at enrollment

Exclusion Criteria:

* apparent genetic, gastrointestinal or metabolic disorders
* artificial ventilation or oxygen supply \> 30% at the time of enrollment
* administration of parenteral fat emulsion (\> 1 g/kg/day for more than seven days) before or after study entry
B: Inclusion Criteria:

* Full term healthy newborn from normal pregnancy
* Newborn whose mother decided to not breastfeed or to stop breastfeed before the third week of life

Exclusion Criteria:

* Newborn with low-birth-weight (\<2500 g)
* Newborn whose parents have planned a move within 6 months after birth
* Family history of allergy to milk protein
C: Inclusion Criteria:

* Gestational age \<= 15th week of gestation
* Age: 18-43 years
* Written informed consent
* Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

* High risk pregnancy
* Hypertonus
* Chronic diseases (i.e. diabetes mellitus)
* Psychiatric diseases
* Former supplementation with LC-PUFA
D: Inclusion Criteria:

* Birth weight \< 1500 g
* Born at one of 4 participating neonatal centers in Norway

Exclusion Criteria:

* Cerebral haemorrhage (stage 3 or 4)
* Major congenital malformations that are supposed to affect growth and development
* Illness that require prolonged parenteral nutrition (\>4 weeks)

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Clinical Trial of the Collaborative Assessment and Management of Suicidality Versus Enhanced Care as Usual for Suicidal Soldiers
Brief Summary: This is a randomized controlled trial comparing the use of new clinical intervention (the "Collaborative Assessment and Management of Suicidality--CAMS") versus enhanced care as usual for suicidal Soldiers who are seen at outpatient mental health clinics at Ft. Stewart GA.


Options:
A: Inclusion Criteria:

* Meet DSM-IV criteria for BPD
* Between 18-60 years of age
* Have had two parasuicide episodes in the past five years with one occurring in the past 3 months
* Have had OHIP coverage for 1 year or more
* Literate in English
* Provide informed consent to participate in the study

Exclusion Criteria:

* Current active substance dependence disorder
* Psychotic disorder,bipolar I disorder, or dementia
* Evidence of an organic brain syndrome or mental retardation
* A chronic or serious physical health problem that will require hospitalization within the next year (e.g. cancer)
* A medical condition that would preclude the psychiatric medication regimen in the GPM condition
* Definite plans to leave the province in the next 2 years
* Currently engaged in DBT or GPM at St. Michael's Hospital
B: Inclusion Criteria:

* diagnosis of DSM-IV Borderline Personality Disorder
* 18-60 years of age
* have had two suicidal or non-suicidal self-injurious behaviours in the past five years with one occurring in the past ten weeks
* be literate in English
* provide informed consent to participate in the study.

Exclusion Criteria:

* not meet DSM-IV criteria for a psychotic disorder, bipolar disorder or, dementia
* not have evidence of an organic brain syndrome or mental retardation based on clinical interview
* not participated in DBT treatment during the past year
C: Inclusion Criteria:

1. 18 years or older.
2. Suicide attempt within the past 60 days defined by intent to die using a standard item.
3. Ability and willingness to provide information and permission to contact at least one person in the case of a need to contact them to promote subject safety or inability to reach the subject for follow-up.

Exclusion Criteria:

1. Acute psychiatric instability (e.g., psychotic symptoms).
2. Inability to communicate in English (ASSIP is only provided by the clinic in English).
3. Residing outside of NYS (during the period eligible for ASSIP)
D: Inclusion Criteria:

* Active duty Army personnel at FSGA
* Significant suicidal ideation
* Soldier is appropriate under FSGA policies
* Consent at baseline and follow up
* Consent to randomization and being digitally recorded

Exclusion Criteria:

* Significant psychosis, cognitive or physical impairment to not give consent
* Judicially ordered treatments

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study
Brief Summary: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.


Options:
A: Inclusion Criteria:

* aged ≥18 years
* able to provide informed consent
* had confirmed HIV infection
* on ART including atazanavir 300 mg and ritonavir 100 mg each day in the regimens that were not changed within 12 weeks before the randomization
* patients who had cholesterol level between 200 and 500 and LDL between 130 and 400 mg/dL without any lipid-lowering agent or discontinued the lipid-lowering agent at least 1 month prior to randomization

Exclusion Criteria:

* had the history of pitavastatin and/or the constituent of the drugs allergy
* known history of myocardial infarction and/or ischemic stroke within 1 month prior to the randomization that would be endangered if we stopped the previous lipid-lowering agent before the enrollment
* abnormal AST and ALT with level ≥5 times in asymptomatic patients or ≥3 times of upper normal limit (UNL) in symptomatic patients
* pregnancy or breastfeeding
* on cyclosporine which had major drug interactions with pitavastatin
* patients who denied to join the study
B: Inclusion Criteria:

* Hypercholesterolemic patients

Exclusion Criteria:

* Patients receiving lipid-lowering agents
* Familial hypercholesterolemia
* Renal disease
* Diseases of liver, gallbladder and bile ducts
* Pregnant women
C: Inclusion Criteria:

* Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
* Both men and women of child bearing potential (i.e., not surgically sterile or post-menopausal defined as age \>40 years without menses for ≥2 years) must agree to use at least 2 reliable forms of contraception
* Documented HIV infection.

Exclusion Criteria:

* Homozygous familial hypercholesterolemia
* Any conditions that may cause secondary dyslipidemia
* History of coronary artery disease (CAD) or CAD equivalent
D: Inclusion Criteria:

* Males and females (18-75 years)
* Must have been following a restrictive diet
* Diagnosis of primary hypercholesterolemia or combined dyslipidemia

Exclusion Criteria:

* Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia;
* Conditions which may cause secondary dyslipidemia.
* Uncontrolled diabetes mellitus (by hemoglobin A1c \[HbA1c\] \> 8%)
* Abnormal serum creatine kinase (CK) above the pre-specified level
* Abnormal pancreatic, liver or renal function
* Significant heart disease

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study
Brief Summary: A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.


Options:
A: Inclusion Criteria:

* HIV Infection with viral load 'undetectable' while taking antiretroviral therapy
* Age ≥40
* Framingham risk score (FRS) ≥5%, or ≥3% with ≥5 years of exposure to antiretroviral therapy

Exclusion Criteria:

* Known cardiovascular disease or Framingham risk score (FRS) ≥20%
* Blood pressure ≥140/90
* LDL cholesterol ≥160 (with FRS \<10%), or ≥130 (with FRS 10-20%)
* Currently taking, or has a medication contraindication to take, a 'statin', an ACE inhibitor, or an angiotensin receptor blocker medication
* Cirrhosis or plasma ALT/AST levels \>2x upper limit of normal
* Chronic kidney disease and a creatinine \>2.0mg/dL
* Triglycerides \>500mg/dL
B: Inclusion Criteria:

* Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
* Both men and women of child bearing potential (i.e., not surgically sterile or post-menopausal defined as age \>40 years without menses for ≥2 years) must agree to use at least 2 reliable forms of contraception
* Documented HIV infection.

Exclusion Criteria:

* Homozygous familial hypercholesterolemia
* Any conditions that may cause secondary dyslipidemia
* History of coronary artery disease (CAD) or CAD equivalent
C: Inclusion Criteria:

* Chronic, well-compensated stable liver
* Hypercholesterolemia

Exclusion Criteria:

* Signs or symptoms of ascites, jaundice, or cirrhosis with a Child-Pugh Score \> 5
* History of disorders affecting serum bilirubin levels, more than 1 chronic liver disease, significant endocrine, renal, or gastrointestinal disease, or uncontrolled hypertension
* Treatment with lipid-lowering drugs, unless they have been withdrawn within the timeframe specified in the protocol
D: Inclusion Criteria:

* at least 30 years of age
* Total Cholesterol between 160 to 400 mg/dl
* \> 3 grandparents of African-American descent or \> 3 grandparents of Caucasian descent
* serum triglycerides \< 400 mg/dl
* fasting glucose \< 126 mg/dl

Exclusion Criteria:

* Use of lipid-lowering medication
* Use of over-the-counter products containing sterol or stanol esters or fish oil
* Recent or planned change in dietary intake or weight change of more than 4.5 kg
* Use of corticosteroids, immunosuppressive drugs or drugs affecting the CYP3A4 system
* Known liver disease or elevated transaminase levels
* Elevated creatine phosphokinase levels \> 10 times upper limits of normal
* Uncontrolled blood pressure, or diabetes mellitus
* Abnormal renal or thyroid function
* Current alcohol or drug abuse
* Major illness in the preceding three months
* Pregnancy
* Know intolerance to statins
* Racial ancestry other than African-American or Caucasian

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Nutritional Status of Iodine in the Pregnant Population of Catalonia: a Study of Dietary Habits and Urinary Iodine
Brief Summary: The purpose of this study is to assess the effectiveness of individual education versus group education about dietary habits and iodine supplementation to decrease iodine deficiency in pregnant women


Options:
A: Inclusion Criteria:

* 12-40 weeks pregnant
* No significant hearing or vision impairment
* English speaking

Exclusion Criteria:

* Active diagnosis of preeclampsia
* Significant hearing or vision impairment
* Non-English speaking
B: Inclusion Criteria:

* Native American pregnant teens or young women ages 12-22 years old at the time of conception.
* Women ages 20-22 years at the time of conception must be pregnant for the first time.
* Partners of pregnant teens must be between the ages of 12-24.
* Pregnant \<28 weeks gestation and able to meet the requirements for completing the program in a timely way.
* An enrolled tribal member.
* Reside in the Reservation Service Unit Catchment Area and within 60 mile of the Indian Health Service Unit Headquarters.

Exclusion Criteria:

* Severe mental illness - schizophrenia, bipolar disorder, incapacitating depression, or Substance abuse/dependence in need of intensive and specific treatment
* Active legal problems - subjects will not be enrolled if they are incarcerated or if program participation has been made a condition of parole
* Ongoing social service involvement for abuse and neglect
C: Inclusion Criteria:

* Pregnant Women in the first trimester
* Over the age of 17
* Receive routine care in their respective health center

Exclusion Criteria:

* Pregnant women who are in the second or third trimester.
* Pregnant women with diagnostic of thyroid disease.
* Pregnant women who do not have a phone.
* Pregnant women with communication difficulties (cognitive or sensory deterioration, language barrier).
* Pregnant women who do not consent to participate in the study.
D: Inclusion Criteria:

* Pregnant and currently at less than 24 weeks gestation
* English- or Spanish-speaking
* Willing to be randomly assigned to either group or individual prenatal care

Exclusion Criteria:

* Any severe medical problems requiring individualized assessment and tracking as a "high-risk pregnancy" (e.g., active substance use, mental illness, HIV)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in IUD Insertion for Nulliparous Women
Brief Summary: The purpose of this study is to see if using misoprostol makes the intrauterine device insertion easier and less painful in women who have never had a baby.


Options:
A: Inclusion Criteria:

* 14 years old or older
* Negative pregnancy test
* No prior pregnancies lasting beyond 19 6/7 weeks
* Minimum 2 weeks after spontaneous or medical abortion
* Minimum 4 weeks post 2nd trimester or surgical abortion
* No previous IUD insertions
* No PID in last 3 months
* No current cervicitis
* Willing to follow-up in 1-2 months for an IUD string check

Exclusion Criteria:

* Active cervical infection
* Current pregnancy
* Prior pregnancy beyond 19 6/7 weeks gestation
* Known uterine anomaly
* Fibroid uterus distorting uterine cavity
* Copper allergy/Wilson's Disease (for Paragard)
* Undiagnosed abnormal uterine bleeding
* Cervical or uterine cancer
B: Inclusion Criteria:

- nulliparous women with no previous history of IUD use

Exclusion Criteria:

* malformation of uterus
* myomas
* acute gynecological infection
* malignant uterine or cervical tumor

In addition if requesting a Cu-IUD

* heavy menstruations
* iron deficiency
* bleeding disorder
* copper allergy or Wilson's disease
C: Inclusion Criteria:

* Nulliparous women (defined as those without a history of pregnancy, despite the outcome, beyond 20 weeks gestation)
* Ages 18-45
* Seeking long-term reversible contraception with an intrauterine device (either Mirena or Paraguard) through the OHSU Center for Women's Health and Planned Parenthood of the Columbia Willamette

Exclusion Criteria:

* Pregnancy occurring less than 6 weeks from time of presentation
* History of prior intrauterine device placement
* History of Mullerian tract anomalies
* History of uterine surgery
* Allergy or intolerance to misoprostol or other prostaglandin
* Pelvic inflammatory disease (current or within the past 3 months)
* Sexually transmitted diseases (current)
* Puerperal or postabortion sepsis (current or within the past 3 months)
* Purulent cervicitis (current)
* Undiagnosed abnormal vaginal bleeding
* Malignancy of the genital tract
* Known uterine anomalies or fibroids distorting the cavity in a way incompatible with intrauterine device insertion
* Allergy to any component of the intrauterine device or Wilson's disease (for copper- containing intrauterine device)
D: Inclusion Criteria:

* age 18-45,
* Generally Healthy.
* requesting LNG-IUS for contraception as the primary indication

Exclusion Criteria:

* previous pregnancy beyond 20 weeks,
* previous IUD placement or attempted placement,
* allergy to nitroprusside,
* history of migraines,
* history of heart disease.

Answer: A